14.02.2017 • NewsElaine BurridgeHuntsmanACC

Huntsman Rejoins American Chemistry Council

(c) Huntsman
(c) Huntsman

After an absence of several years, Huntsman has rejoined the American Chemistry Council (ACC), with president and CEO Peter Huntsman taking up a position on the ACC’s executive committee and board of directors.

“We are enthusiastic about joining the ACC and look forward to working with them to address many of the challenges facing our industry. Under the leadership of ACC president and CEO Cal Dooley, the organization has a proven track record of success and has been an effective industry advocate for the critical role we play in the lives of people around the world,” said Peter Huntsman.

Huntsman added that membership in the ACC was consistent with the company's values, including stakeholder engagement, sustainability, sound science and technology leadership.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.